FDA Approves Botox Indication For Treatment of Chronic Migraines

The Food and Drug Administration Oct. 15 announced that it has approved Botox injection (onabotulinumtoxinA) to prevent headaches in adult patients with chronic migraine.

Chronic migraine is defined as having a history of migraine and experiencing a headache on most days of the month, FDA said. To treat chronic migraines, Botox is given approximately every 12 weeks as multiple injections around the head and neck to try to dull future headache symptoms. Botox is manufactured by Allergan Inc. of Irvine, Calif.

“Chronic migraine is one of the most disabling forms of headache,” Russell Katz, director of the Division of Neurology ...